NovoCure (NASDAQ: NVCR) insider transactions

In the twelve months to 10 November 2026, executives and directors of NovoCure reported 26 open-market sales of 228,821 shares ($3.3m) and 0 open-market purchases, by 14 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in NovoCure shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
2 November 2026	Puri Michal Nath	Chief Human Resources Officer	Open-market sale	−660	$13.24	202,567	Form 4
30 June 2026	Danziger Asaf	Director	Grant or award	+268	$11.15	416,742	Form 4
30 June 2026	Leonard Frank X	Chief Executive Officer	Grant or award	+1,905	$11.15	461,425	Form 4
30 June 2026	Ben Arye Barak	General Counsel	Grant or award	+1,299	$11.15	243,752	Form 4
30 June 2026	Puri Michal Nath	Chief Human Resources Officer	Grant or award	+1,905	$11.15	203,227	Form 4
4 June 2026	Leonard Frank X	Chief Executive Officer	Open-market sale	−34,273	$17.93	459,520	Form 4
3 June 2026	Hilleman Jeryl L	Director	Grant or award	+11,610	—	25,471	Form 4
3 June 2026	Leung Gabriel	Director	Grant or award	+11,610	—	101,109	Form 4
3 June 2026	Hung David	Director	Grant or award	+11,610	—	32,075	Form 4
3 June 2026	Vernon W Anthony	Director	Grant or award	+11,610	—	209,267	Form 4
3 June 2026	Scannell Timothy J	Director	Grant or award	+11,610	—	25,898	Form 4
3 June 2026	Madden Martin J.	Director	Grant or award	+11,610	—	30,284	Form 4
3 June 2026	Ocean Allyson J	Director	Grant or award	+11,610	—	22,934	Form 4
3 June 2026	Stafford Kristin	Director	Grant or award	+11,610	—	22,934	Form 4
2 June 2026	Hilleman Jeryl L	Director	Open-market sale	−2,945	$15.77	13,861	Form 4
2 June 2026	Leung Gabriel	Director	Open-market sale	−2,945	$15.77	89,499	Form 4
2 June 2026	Hung David	Director	Open-market sale	−2,945	$15.77	20,465	Form 4
2 June 2026	Vernon W Anthony	Director	Open-market sale	−2,945	$15.77	197,657	Form 4
2 June 2026	Scannell Timothy J	Director	Open-market sale	−2,945	$15.77	14,288	Form 4
2 June 2026	Ocean Allyson J	Director	Open-market sale	−2,945	$15.77	11,324	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the NovoCure page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.